US 11,690,898 B2
Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
Stuart Bunting, Novato, CA (US); Peter Cameron Colosi, Novato, CA (US); and Erno Pungor, Novato, CA (US)
Assigned to BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed by BIOMARIN PHARMACEUTICAL INC., Novato, CA (US)
Filed on Nov. 6, 2019, as Appl. No. 16/675,841.
Application 16/675,841 is a division of application No. 15/274,046, filed on Sep. 23, 2016, granted, now 10,512,675.
Claims priority of provisional application 62/365,544, filed on Jul. 22, 2016.
Claims priority of provisional application 62/323,182, filed on Apr. 15, 2016.
Claims priority of provisional application 62/232,242, filed on Sep. 24, 2015.
Prior Publication US 2020/0061161 A1, Feb. 27, 2020
Int. Cl. C12N 15/864 (2006.01); A61K 38/37 (2006.01); A61K 48/00 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 39/12 (2006.01); C07K 14/755 (2006.01); A61K 47/02 (2006.01); C12N 7/00 (2006.01); G01N 33/68 (2006.01)
CPC A61K 38/37 (2013.01) [A61K 39/12 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 48/0008 (2013.01); A61K 48/0075 (2013.01); C07K 14/755 (2013.01); C12N 7/00 (2013.01); G01N 33/6854 (2013.01); C12N 2710/16044 (2013.01); C12N 2750/14121 (2013.01); C12N 2750/14141 (2013.01); C12N 2750/14143 (2013.01); G01N 2333/015 (2013.01)] 6 Claims
 
1. A pharmaceutical formulation comprising a recombinant AAV FVIII virus, sodium phosphate at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml, mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml, and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml.